1 0
Cart
    Inquiry
    Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein

    ERBB2

    Loading...

    Anti-ERBB2 Products

    + Filter
    Loading...
    • Anti-Her2-mc-vc-PABC-MMAE ADC (ADC-175LZY)
      • Target: Her2
      • Linker: mc-VC-PABC (maleimidocaproyl valine-citrulline-p-aminobenzyl carbamoyl)
      • Drug: MMAE (monomethyl auristatin E)
      Go to compare Compare
    • Anti-HER2-Gly5-modified DM1 ADC (ADC-147CL)
      • Target: HER2
      • Drug: Gly5-modified DM1 (Gly5-modified N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
      Go to compare Compare
    • Anti-HER2-vcPAB-MMAE ADC (ADC-148CL)
      • Target: HER2
      • Linker: VC-PAB (valine-citrulline-p-aminobenzoyloxycarbonyl)
      • Drug: MMAE (Monomethyl auristatin E)
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-295CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-Her2-VCP-cyclooctyne-MMAF ADC (ADC-210CL)
      • Target: Her2
      • Linker: valine-citruline-p-amino-benzoyl-carbonate (VCP)-cyclooctyne
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-296CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-297CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-298CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-299CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-300CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-MT-vc-MMAE ADC (ADC-248CL)
      • Target: HER2
      • Linker: MT-VC
      • Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-307CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-NGMs-MMAE ADC (ADC-035LZY)
      • Target: HER2
      • Linker: NGMs(next generation maleimides)
      • Drug: MMAE (monomethyl auristatin E)
      Go to compare Compare
    • Anti-HER2-BMPEO-DM1 ADC (ADC-186CL)
      • Target: HER2
      • Linker: BMPEO (bis-maleimido-trioxyethylene glycol)
      • Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-308CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-DBM-MMAF ADC (ADC-105LZY)
      • Target: HER2
      • Linker: DBM(dibromomaleimide)
      • Drug: MMAF(monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-MT-vc-MMAE ADC (ADC-249CL)
      • Target: HER2
      • Linker: MT-VC
      • Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-309CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-mc-MMAF ADC (ADC-107LZY)
      • Target: HER2
      • Linker: mc(maleimidocaproyl)
      • Drug: MMAF(monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-310CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-Her2-vc-[14C]MMAE ADC (ADC-221LZY)
      • Target: Her2
      • Linker: VC(valine-citrulline)
      • Drug: [14C]MMAE(14C-labeled monomethyl auristatin E)
      Go to compare Compare
    • Anti-HER2-MT-vc-MMAE ADC (ADC-250CL)
      • Target: HER2
      • Linker: MT-VC
      • Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-HER2-DBCO-MMAF ADC (ADC-311CL)
      • Target: HER2
      • Linker: DBCO (Dibenzocyclooctyl)
      • Drug: MMAF (Monomethyl auristatin F)
      Go to compare Compare
    • Anti-HER2-MT-vc-MMAE ADC (ADC-251CL)
      • Target: HER2
      • Linker: MT-VC
      • Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-HER2-DOX ADC (ADC-131LZY)
      • Target: HER2
      • Linker: thiomaleamicacids-p-aminobenzyloxycarbonyl
      • Drug: doxorubicin
      Go to compare Compare
    • Anti-HER2-DUBA-Duocarmycins ADC (ADC-069LZY)
      • Target: HER2
      • Linker: DUBA (DUocarmycinhydroxyBenzamide-Azaindole
        linker) ("mc"-VC-PABC-CM)
      • Drug: Duocarmycins
      Go to compare Compare
    • Anti-HER2-MT-vc-MMAE ADC (ADC-252CL)
      • Target: HER2
      • Linker: MT-VC
      • Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-HER2-SPP-DM1 ADC (ADC-132LZY)
      • Target: HER2
      • Linker: SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
      • Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
      Go to compare Compare
    • Anti-HER2 (trastuzumab)-SPDP-DM1 ADC (ADC-134LCT)
      • Target: HER2
      • Linker: SPDP ( N-succinimidyl 3-(2-pyridyldithio)propionate)
      • Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
      Go to compare Compare
    • Anti-HER2-MT-vc-MMAE ADC (ADC-253CL)
      • Target: HER2
      • Linker: MT-VC
      • Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-HER2-vc-MMAE ADC (ADC-081LZY)
      • Target: HER2
      • Linker: VC (valine-citrulline)
      • Drug: MMAE(monomethyl auristatin E)
      Go to compare Compare
    • Anti-HER2-[14C]-SMCC-DM1 ADC (ADC-150LZY)
      • Target: HER2
      • Linker: [14C]-SMCC
      • Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
      Go to compare Compare
    • Anti-HER2 (trastuzumab)-SPP-DM1 ADC (ADC-135LCT)
      • Target: HER2
      • Linker: SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
      • Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
      Go to compare Compare
    • Anti-HER2-MT-vc-MMAE ADC (ADC-254CL)
      • Target: HER2
      • Linker: MT-VC
      • Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-HER2-MP(T-vc)-MMAE ADC (ADC-255CL)
      • Target: HER2
      • Linker: MP(T-VC)
      • Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino) phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-HER2-MC-vc-PABC-MMAE ADC (ADC-256CL)
      • Target: HER2
      • Linker: MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
      • Drug: (S,E)-N-(4-(aminomethyl)benzylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-HER2 (trastuzumab)-auristatin ADC (ADC-138LCT)
      • Target: HER2
      • Linker: The linker contains two ethylene glycol moieties modified with a terminal alkoxy-amine group to improve solubility and minimize export of the more hydrophilic derivatized analogs by drug pumps
      • Drug: auristatin
      Go to compare Compare
    • Anti-HER2-MT-vc-MMAE ADC (ADC-257CL)
      • Target: HER2
      • Linker: MT-VC
      • Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-HER2-SMCC-DM1 ADC (ADC-001LZY)
      • Target: HER2
      • Linker: SMCC (N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate)
      • Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
      Go to compare Compare
    • Anti-HER2-MT-vc-MMAE ADC (ADC-258CL)
      • Target: HER2
      • Linker: MT-VC
      • Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
      Go to compare Compare
    • Anti-Her2-MCC-DM1 ADC (ADC-174LZY)
      • Target: Her2
      • Linker: MCC (Maleimidomethyl cyclohexane-1-carboxylate)
      • Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
      Go to compare Compare
    View More Products

    Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

    More Infomation

    Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    For Research Use Only. Not For Clinical Use.


    Background

    This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
    ERBB2
    Protein class

    Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins

    Predicted location

    Intracellular, Membrane (different isoforms)

    Single cell type specificity

    Cell type enhanced (Collecting duct cells, Proximal enterocytes, Distal enterocytes)

    Immune cell specificity

    Immune cell enhanced (gdT-cell)

    Cell line specificity

    Group enriched (OE19, SK-BR-3)

    Interaction

    Homodimer (PubMed:21454582). Heterodimer with EGFR, ERBB3 and ERBB4 (PubMed:10358079, PubMed:15093539, PubMed:21190959, PubMed:16978839). Part of a complex with EGFR and either PIK3C2A or PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196 (PubMed:10805725). Interacts with PLXNB1 (PubMed:15210733). Interacts (when phosphorylated on Tyr-1248) with MEMO1 (PubMed:15156151). Interacts with MUC1; the interaction is enhanced by heregulin (HRG) (PubMed:12939402). Interacts (when phosphorylated on Tyr-1139) with GRB7 (via SH2 domain) (PubMed:12975581). Interacts (when phosphorylated on Tyr-1248) with ERBIN (PubMed:12444095). Interacts with KPNB1, RANBP2, EEA1, CRM1 and CLTC (PubMed:16314522). Interacts with PTK6 (PubMed:18719096). Interacts with RPA194 and ACTB (PubMed:21555369). Interacts with PRKCABP, SRC and MYOC (By similarity). Interacts (preferentially with the tyrosine phosphorylated form) with CPNE3; this interaction occurs at the cell membrane and is increased in a growth factor heregulin-dependent manner (PubMed:20010870). Interacts with HSP90AA1 and HSP90AB1 in an ATP-dependent manner; the interaction suppresses ERBB2 kinase activity (PubMed:26517842). Interacts with SORL1; this interaction regulates ERBB2 subcellular distribution by promoting its recycling after internalization from endosomes back to the plasma membrane, hence stimulates ERBB2-mediated signaling (PubMed:31138794).

    Molecular function

    Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase

    More Types Infomation
    Related Diseases
    Bladder Cancer Bladder Cancer
    Non-small Cell Lung Cancer Non-small Cell Lung Cancer
    Related Signaling Pathways
    ErbB Signaling Pathway ErbB Signaling Pathway
    Go to compare

    Go to compare